• Home
  • Company
  • Our Lead Product
  • Pipeline
  • News-Media
  • Contact Us
  • Home
  • Company
  • Our Lead Product
  • Pipeline
  • News-Media
  • Contact Us

Pipeline

Startseite » Pipeline
European Medicines Agency Grants PRIME Designation to BIT Pharma’s NicaPlant® for Treatment of Non-traumatic Subarachnoid Haemorrhage in Patients undergoing Surgery. 19. October 2022
Pipeline
European Medicines Agency Grants PRIME Designation to BIT Pharma’s NicaPlant® for Treatment of Non-traumatic Subarachnoid Haemorrhage in Patients undergoing Surgery.
BIT Pharma Announces the Presentation of NicaPlant® Phase 2 Results at International Conferences 31. August 2022
Pipeline
BIT Pharma Announces the Presentation of NicaPlant® Phase 2 Results at International Conferences
BIT Pharma Announces Positive Phase 2b Study Results for NicaPlant® in Aneurysmal Subarachnoid Heamorrhage patients (aSAH) undergoing aneurysm clipping. 1. July 2022
Pipeline
BIT Pharma Announces Positive Phase 2b Study Results for NicaPlant® in Aneurysmal Subarachnoid Heamorrhage patients (aSAH) undergoing aneurysm clipping.
NICAPLANT GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION 27. December 2019
Pipeline
NICAPLANT GRANTED ORPHAN MEDICINAL PRODUCT DESIGNATION
BIT PHARMA ANNOUNCES SUCCESSFUL COMPLETION OF NicaPlant PHASE 2a CLINICAL TRIAL 6. July 2019
Pipeline
BIT PHARMA ANNOUNCES SUCCESSFUL COMPLETION OF NicaPlant PHASE 2a CLINICAL TRIAL
LEAD PRODUCT
NicaPlant®
BIT PHARMA
Company
Lead Product
Pipeline
Team and Management
Scientific Literature
News-Media
Contact
LEGAL
Privacy Policy
Copyright

Funded by seed financing of the BMWFW, processed by Austria Wirtschafts Service.


BMWFW

Austria Wirtschaftsservice
© 2016 BIT Pharma. All Rights Reserved.
Contact Us

Send us an email for further inquiry.

Not readable? Change text.